The Concise Guide to Pharmacology 2013/14: Overview

The Concise Guide to PHARMACOLOGY 2013/14 provides concise overviews of the key properties of over 2000 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties from the IUPHAR database. The full contents can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.12444/full.

Adam J Pawson | Stephen P. H. Alexander | A. A. Khan | J. Siegel | R. Neubig | D. Sibley | D. Fabbro | C. Dollery | T. Bonner | M. Arita | R. Leurs | L. Schild | W. Catterall | R. Vandenberg | S. Bröer | A. Schousboe | R. Hauger | W. Carter | M. Hollenberg | M. Spedding | A. Dolphin | J. Pin | J. Cidlowski | M. Panaro | E. Faccenda | J. Sharman | A. Davenport | G. Sanger | H. E. Benson | J. A. Peters | A. Harmar | T. Hales | R. Sitsapesan | D. Thwaites | B. Mouillac | R. Roskoski | E. Prossnitz | M. Chao | M. Donowitz | E. Ohlstein | N. Pyne | M. Dubocovich | S. Offermanns | J. Quigley | D. MacEwan | G. Fitzgerald | N. Chiang | Athanasios Christopoulos | I. Goldman | A. Bennett | D. Poyner | J. Maguire | N. Millar | E. Lingueglia | C. Fahlke | C. Fowler | E. Barker | R. Farndale | R. Ross | E. Richelson | D. Belelli | B. A. Evans | G. Dent | L. Stoddart | J. McGrath | J. M. May | C. Villalón | M. Vore | S. Lolait | J. Petersen | E. Wright | G. Jarvis | G. Singh | F. Dautzenberg | V. Ganapathy | M. Roth | J. Hancox | C. Anderson | S. Schulz | J. Neumaier | D. Boison | V. Mitolo | N. Birdsall | N. Abul-Hasn | M. S. Araiksinen | E. Arthofer | C. Barratt | N. Barnes | R. Bathgate | P. Beart | L. Brailsford | P. Brown | G. Calò | S. L. Chan | J. Chun | D. Clapham | S. Cockcroft | M. Connor | H. Cox | A. Cuthbert | P. Dawson | J. Dijksterhuis | L. Eiden | K. Eidne | T. Fong | J. Fry | C. D. Funk | A. Futerman | B. Gaisnier | M. Gershengorn | A. Goldin | A. Gundlach | B. Hagenbuch | J. Hammond | M. Hamon | D. Hay | A. Hobbs | N. Holliday | D. Hoyer | N. Hynes | Kiwamu Inui | S. Ishii | K. Jacobson | M. Jarvis | R. Jensen | C. E. Jones | R. Jones | K. Kaibuchi | Y. Kanai | C. Kennedy | I. Kerr | M. J. Klienz | J. Kukkonen | J. Lapoint | J. Lippiat | S. Lummis | J. Lynch | I. Marshall | C. McArdle | M. Michel | L. Miller | P. Monk | P. Moore | A. Moorhouse | P. Murphy | B. Niesler | A. Obaidat | S. Parsons | R. G. Pwrtwee | S. Prigent | S. Pyne | R. Ramachandran | R. Roberts | G. Rudnick | R. Ryan | S. I. Said | K. Scholich | G. Schulte | C. Serhan | P. Sexton | T. Smart | D. M. Smith | T. Soga | A. Ståhl | G. Stewart | R. Summers | B. Thorens | L. Toll | J. Traynor | T. Usdin | S. Waldman | D. Ward | G. Willars | S. Wonnacott | R. Ye | A. Yonezawa | M. Zimmermann | G. FitzGerald | C. E. Jones

[1]  L. Agellon,et al.  Transport and biological activities of bile acids. , 2013, The international journal of biochemistry & cell biology.

[2]  H. Lodish,et al.  T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[3]  J. Sacchettini,et al.  Structural studies on human muscle fatty acid binding protein at 1.4 A resolution: binding interactions with three C18 fatty acids. , 1994, Structure.

[4]  J C Sacchettini,et al.  Crystal structure of rat intestinal fatty-acid-binding protein. Refinement and analysis of the Escherichia coli-derived protein with bound palmitate. , 1989, Journal of molecular biology.

[5]  Philippe Froguel,et al.  Cloning of adiponectin receptors that mediate antidiabetic metabolic effects , 2003, Nature.

[6]  Stephen P. H. Alexander,et al.  Guide to Receptors and Channels (GRAC), 5th edition , 2011, British journal of pharmacology.

[7]  S. Okuyama,et al.  NE-100, a novel sigma receptor ligand: in vivo tests. , 1993, Life sciences.

[8]  A. Kleinfeld,et al.  Fatty acid binding proteins from different tissues show distinct patterns of fatty acid interactions. , 2000, Biochemistry.

[9]  L. Banaszak,et al.  The Crystal Structure of the Liver Fatty Acid-binding Protein , 1997, The Journal of Biological Chemistry.

[10]  J. Storch,et al.  Tissue-specific Functions in the Fatty Acid-binding Protein Family* , 2010, The Journal of Biological Chemistry.

[11]  J A Peters,et al.  Guide to Receptors and Channels (GRAC), 3rd edition , 2008, British journal of pharmacology.

[12]  P. Scherer,et al.  Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. , 2009, Trends in pharmacological sciences.

[13]  Yitao Wang,et al.  Adiponectin, an unlocking adipocytokine. , 2009, Cardiovascular therapeutics.

[14]  M. Spedding,et al.  X. International Union of Pharmacology recommendations for nomenclature of new receptor subtypes. , 1996, Pharmacological reviews.

[15]  J C Sacchettini,et al.  Crystal structure and thermodynamic analysis of human brain fatty acid-binding protein. , 2000, The Journal of biological chemistry.

[16]  A. Beck‐Sickinger,et al.  Molecular tools to characterize adiponectin activity. , 2012, Vitamins and hormones.

[17]  M. Record,et al.  Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands. , 2011, Chemistry and physics of lipids.

[18]  J. Suttles,et al.  Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins. , 2009, Journal of medicinal chemistry.

[19]  D. W. Parish,et al.  Sigma compounds derived from phencyclidine: identification of PRE-084, a new, selective sigma ligand. , 1991, The Journal of pharmacology and experimental therapeutics.

[20]  Feng Liu,et al.  APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function , 2006, Nature Cell Biology.

[21]  E. Polverini,et al.  Structural and Functional Characterization of Human Peripheral Nervous System Myelin Protein P2 , 2010, PloS one.

[22]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[23]  D. Bok,et al.  Structural and functional characterization of recombinant human cellular retinaldehyde‐binding protein , 1998, Protein science : a publication of the Protein Society.

[24]  B. Dubrovsky.  Neurosteroids, neuroactive steroids, and symptoms of affective disorders , 2006, Pharmacology Biochemistry and Behavior.

[25]  M. Fasshauer,et al.  Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease? , 2012, Diabetologia.

[26]  R. Mach,et al.  The analgesic tropane analogue (±)-SM 21 has a high affinity for σ2 receptors , 1999 .

[27]  A. Chmurzyńska.  The multigene family of fatty acid-binding proteins (FABPs): Function, structure and polymorphism , 2010, Journal of Applied Genetics.

[28]  Xinliang Ma,et al.  Protective vascular and myocardial effects of adiponectin , 2009, Nature Clinical Practice Cardiovascular Medicine.

[29]  C. Mantzoros,et al.  The role of adiponectin in cancer: a review of current evidence. , 2012, Endocrine reviews.

[30]  G. Li Volti,et al.  Novel sigma receptor ligands: synthesis and biological profile. , 2007, Journal of medicinal chemistry.

[31]  H. van Tilbeurgh,et al.  Expression, purification, and crystal structure determination of recombinant human epidermal-type fatty acid binding protein. , 1999, Biochemistry.

[32]  W. Bowen,et al.  Characterization of two novel σ receptor ligands: antidystonic effects in rats suggest σ receptor antagonism , 1995 .

[33]  X. Codony,et al.  Sigma receptors: biology and therapeutic potential , 2004, Psychopharmacology.

[34]  T. Matsuo,et al.  Classification of FABP isoforms and tissues based on quantitative evaluation of transcript levels of these isoforms in various rat tissues , 2009, Biotechnology Letters.

[35]  Megan Lerner,et al.  σ Receptors: potential medications development target for anti-cocaine agents , 2003 .

[36]  H. R. Payne,et al.  Role of Fatty Acid Binding Proteins and Long Chain Fatty Acids in Modulating Nuclear Receptors and Gene Transcription , 2007, Lipids.

[37]  A. Kleinfeld,et al.  Equilibrium constants for the binding of fatty acids with fatty acid-binding proteins from adipocyte, intestine, heart, and liver measured with the fluorescent probe ADIFAB. , 1994, The Journal of biological chemistry.

[38]  R. Parker,et al.  Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 , 2007, Nature.

[39]  M. Furuhashi,et al.  Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets , 2008, Nature Reviews Drug Discovery.

[40]  David S. Taylor,et al.  Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). , 2007, Bioorganic & medicinal chemistry letters.

[41]  New sigma and 5-HT1A receptor ligands: omega-(tetralin-1-yl)-n-alkylamine derivatives. , 1996, Journal of medicinal chemistry.

[42]  T. Arumugam,et al.  Adiponectin receptor signalling in the brain , 2012, British journal of pharmacology.